Ownership history in Siren, L.L.C. Β· 4 quarters on record
This page tracks every 13F SEC filing in which Siren, L.L.C. reported a position in Sionna Therapeutics Inc (SION). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Siren, L.L.C. outperformed the S&P 500 by +204.9% annually on this SION position. Average cost basis: $10.46. Maximum drawdown during holding period: β0.0%.
π₯ Exceptional β beat the S&P 500 by 204.9% per year on this position.
3 quarters analyzed
Best entry: $10.46 (2025 Q1) Β· Worst: $10.46 (2025 Q1)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
1 add Β· 1 trim. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.37% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size